Vestal Point Capital, LP Immatics N.V. Transaction History
Vestal Point Capital, LP
- $1.69 Trillion
- Q4 2024
A detailed history of Vestal Point Capital, LP transactions in Immatics N.V. stock. As of the latest transaction made, Vestal Point Capital, LP holds 6,275,000 shares of IMTX stock, worth $28.6 Million. This represents 2.65% of its overall portfolio holdings.
Number of Shares
6,275,000
Previous 3,750,000
67.33%
Holding current value
$28.6 Million
Previous $42.8 Billion
4.27%
% of portfolio
2.65%
Previous 3.24%
Shares
5 transactions
Others Institutions Holding IMTX
# of Institutions
93Shares Held
92.5MCall Options Held
313KPut Options Held
377K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.6MShares$48.3 Million0.05% of portfolio
-
Wellington Management Group LLP Boston, MA10.4MShares$47.4 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$42.7 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$33.1 Million0.57% of portfolio
-
Rtw Investments, LP New York, NY6.54MShares$29.8 Million0.76% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $347M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...